Nkarta, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NKTX research report →
About the company
Nkarta, Inc. , a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.
- CEO
- Paul J. Hastings
- IPO
- 2020
- Employees
- 108
- HQ
- South San Francisco, CA, US
Price Chart
- Market Cap
- $230.38M
- P/E
- -2.40
- P/S
- 0.00
- P/B
- 0.84
- EV/EBITDA
- -3.07
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -30.90%
- ROIC
- -32.22%
- Revenue
- $0 · 0.00%
- Net Income
- $-104,084,000 · 4.33%
- EPS
- $-1.41 · 11.88%
- Op Income
- $-121,206,000
- FCF YoY
- 13.64%
- 52W High
- $3.65
- 52W Low
- $1.68
- 50D MA
- $2.89
- 200D MA
- $2.34
- Beta
- 0.92
- Avg Volume
- 783.89K
Get TickerSpark's AI analysis on NKTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 18, 26 | HASTINGS PAUL J | sell | 1,776 |
| Jun 10, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 37,000 |
| Jun 10, 26 | Behbahani Ali | other | 37,000 |
| Jun 10, 26 | George Simeon | other | 37,000 |
| Jun 10, 26 | Vratsanos George | other | 37,000 |
| Jun 10, 26 | Scheiner Zachary | other | 37,000 |
| Jun 10, 26 | PATTERSON LEONE D | other | 37,000 |
| Jun 10, 26 | Dybbs Michael | other | 37,000 |
| Jun 10, 26 | Thedinga Angela | other | 37,000 |
| Jan 15, 26 | HASTINGS PAUL J | sell | 26,046 |
Our NKTX coverage
Recent articles, reports, and earnings notes.
No research on NKTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NKTX report →Similar companies
Peers in the same neighborhood.